相关实验视频

Updated: Jul 5, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

在脂质肉瘤中发生的遗传,表观遗传和转录组变化,用于选择向治疗

Ekaterina A Lesovaya^1,2,3, Timur I Fetisov¹, Beniamin Yu Bokhyan¹

¹N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia.

|January 23, 2024

概括

脂质肉瘤是一种常见的软组织肉瘤,由于其多样性,它存在治疗挑战. 了解其分子和表观遗传变化是开发向疗法,如CDK4/6和MDM2抑制剂的关键.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

脂质肉瘤 (LPS) 是一种流行成人软组织肉瘤 (STS),具有多样化的组织病理和分子特征.
目前对晚期LPS的治疗方法有限,手术切除是局部疾病的首要方法.
脊椎病的异质性使得有效的向治疗方法的开发变得复杂.

研究的目的:

审查脂肉瘤亚型中的分子遗传学和表观遗传变化.
讨论涉及LPS病变发生的关键信号通路.
探索基于亚型特定特征的LPS新,生物驱动的治疗策略.

主要方法:

对脂肪肉瘤的分子遗传学和表观遗传变化的全面分析.
审查涉及脂肪肉瘤发展的信号级联.
评估新兴的向疗法及其临床前/临床研究状态.

主要成果:

识别不同类型脂肪肉瘤亚型的特定分子和表观遗传变化.
关键信号通路的阐明驱动脂肪肉瘤的进展.
有望的临床前和临床数据针对目标药物,包括CDK4/6和MDM2抑制剂,以及多酶抑制剂 (anlotinib,sunitinib).

结论:

更深入地了解脂肪瘤的分子和表观遗传景观对于推进治疗至关重要.
向疗法,特别是CDK4/6,MDM2抑制剂和多酶抑制剂,对LPS有显著的前景.
解决治疗耐药性和瘤异质性的问题对于新疗法的成功临床转化至关重要.

关键词:

没有区分的脂肪肉瘤.表观遗传变化表观遗传变化脂肪肉瘤 (liposarcoma) 是一种分子遗传异常是分子遗传异常.状形形脂质肉瘤 (myxoid pleomorphic liposarcoma) 是一种多样性的癌症.状细胞/圆细胞脂肪肉瘤 pleomorphic 脂质肉瘤是一种多态的脂质肉瘤.有针对性的治疗.区分良好的脂肪肉瘤.

更多相关视频

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...